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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use 
of  30 mL Cerebrolysin is a safe and effective drug for improving global and cognitive function 
in patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities.  
STUDY DESIGN: Systematic review of three randomized controlled trials published between 
2001-2006, all English language. 
DATA SOURCES: Three randomized controlled trials comparing the efficacy of cerebrolysin to 
placebo in the treatment of individuals ages 50 and over with AD related cognitive and global 
functioning decline. All articles found using PubMed. 
OUTCOMES MEASURED: Three randomized controlled studies measured improvement in 
cognitive and global impairment in patients with AD using a combination of either ADAS-
cog(clinician rated test measuring cognitive function), CIBIC+(clinician based interview of 
patient to assess global change), or CGI(clinician assessment of mental deterioration). The 
evaluations cover orientation, memory, language, understanding, behavior, and activities of daily 
living. Evaluations with the tests mentioned were made under double-blind conditions.  
RESULTS: Three randomized controlled trials were included in this review. Ruether et al.  
revealed a significant effect on functional and cognitive decline with 30mL Cerebrolysin. 
Panisset et al. found a significant relationship between Cerebrolysin and improved global 
functioning, but no change in cognition between experimental and control groups. Alverez et al. 
found insignificant effects on both cognition and global functioning.  
CONCLUSIONS: The results of the three studies represent inconclusive evidence that 
Cerebrolysin has significant effects on cognition and global functions in patients with AD. One 
study found significant improvements in cognition and global function, but the other studies 
found insignificant effects. Further studies are encouraged to develop a definitive relationship.  
KEY WORDS: cerebrolysin, alzheimer’s disease, randomized 
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INTRODUCTION  
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. It is 
characterized by progressive behavioral and cognitive deficits accompanied by diffuse structural 
abnormalities in the brain.4 Cerebrolysin, a peptide solution, may have the properties to stabilize 
neurons and decrease amyloid production to improve cognition and global functioning in patients 
with AD.  
An estimated 10% of patients age 70 years and older have significant memory loss, and 
over half of that population contribute the memory loss to AD.6 It is the most common cause of 
dementia in the elderly and the sixth leading cause of death in the US.4,7 There are around 125 
new cases per 100,000 people annually for ages 60 and over and around 3,200 new cases per 
100,000 for those 70 to 79.5  An estimated 5.2 million Americans have AD in 2013.7 As the 
number of Americans surviving into 80s and beyond continues to grow, and the baby boomer 
generation ages, it can be assumed Alzheimer’s disease will become even more prevalent in the 
future. 
 The estimate costs to care for an elderly patient with AD for one year are around 
$50,000.6 Furthermore, the US as a whole spends close to $100 billion annually to care for 
patients with AD.4 A large burden is also placed on unpaid caregivers who provided an estimated 
17.5 billion hours of unpaid care in 2012, valued at more than $216 billion. The annual drug cost 
for Cerebrolysin has not been identified. In 2008, 349 patients required stays in skilled nursing 
facilities per 1,000 Medicare beneficiaries with Alzheimer’s and other dementias. Also, there 
were 780 hospital stays per 1,000 Medicare beneficiaries for those age 65 and older with AD or 
other dementias.7  
AD Pathology hallmarks include amyloid plaques, neurofibrillary tangles, and diffuse 
loss of neurons and synapses.5 Neuronal and synapse loss primarily in the subcortical regions of 
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the brain. It is known that amyloid is toxic to neurons and synapses but the pathophysiology is 
not completely understood. There is loss of cortical proteins and neurotransmitters like 
acetylcholine and nicotinic cholinergic receptors.5 Also, noradrenergic and serotonergic 
depletion from further degeneration subcortical brain regions.5  Symptoms include language 
impairment, memory loss, agitation, anxiety, memory loss, apraxia, impaired executive function, 
and sleep disorders.4,5,6 
Due to the complexity of the pathologic process involved in AD the conventional 
treatments to date focus on symptomatic benefit.  Usual methods for treating AD consists of 
acetylcholinesterase inhibitors which increase levels of Acetylcholine available at the synaptic 
cleft. Conventional acetylcholinesterase inhibitors include tacrine, donepezil, rivastigmine, 
and galantamine. NMDA receptor blockers, such as memantine, are used as adjunctive treatment 
to stabilize cognition and function primarily in moderate and severe disease. Non-traditional 
treatments include Axona, which provides an alternative fuel source of ketones for brain. 
Pharmaceuticals such as trazodone, haloperidol, thioridazine, risperidone help behavioral and 
sleep disorders associated with Alzheimer’s disease. All of the medications available are 
centered on symptomatic relief and are effective for a limited time. The focus of current drug 
development aims at stabilization strategies to delay the disease process. 
The method of treatment with Cerebrolysin is being proposed because currently there is 
no cure for Alzheimer’s disease; although the medications above have seemed to temporarily 
improve symptoms of patients with AD. Cerebrolysin may be used as an IV alternative for the 
stabilizing the disease process, relief of symptoms associated with AD, and improving activities 
of daily living. This selective evidence-based medicine review evaluated three double-blind, 
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randomized controlled trials comparing the efficacy of Cerebrolysin as an IV medication for 
improving global and cognitive function in patients 50 years and older with AD. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not the use of 30 
mL Cerebrolysin is a safe and effective drug for improving global and cognitive function in 
patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities. 
METHODS 
 The populations criteria used for selection in the studies included men and women age 50 
year and older with Alzheimer’s disease. The interventions studied in the RCTs was 
Cerebrolysin 30 mL IV infusion. Comparisons was made between the treatment group receiving 
Cerebrolysin to the experimental group who received a visually matched Placebo. Outcomes 
measured involved the efficacy and tolerability of Cerebrolysin for the treatment of AD, and 
improvement in cognitive and global functioning. The types of studies included were three 
randomized, double-blind, placebo controlled clinical trials. 
The key words used in the searches were “Alzheimers disease,” “Cerebrolysin,” and 
“randomized.” All articles were published in peer reviewed journals in the English language. The 
author searched articles via PubMed and Cochrane library, and articles were selected based on 
their relevance to the clinical question and inclusion of patient oriented outcomes(global 
functioning and cognition). Inclusion criteria consisted of studies in which the design was 
randomized, controlled, double blind, and patient-oriented outcomes(POEMs). Exclusion criteria 
consisted of studies with patients under 50 years old or non-Alzheimer’s form of dementia. The 
summary of statistics are reported using relative benefit increase(RBI), absolute benefit 
increase(ABI), numbers needed to treat(NNT), 95% confidence interval(CI), and p-value. 
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Table 1 – Demographics & Characteristics of included studies 
Study Type # Pts Age(yrs) Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Alvarez1 
(2006) 
Double 
blind 
RCT 
279 50+ diagnosis of 
AD, mini 
mental state 
exam(MMSE) 
scores from 
14-25, Mod. 
Ischemia 
scale score 
≤4, CT/MRI 
within 12 
months 
Pt with any 
psychiatric 
disorder, or 
psychoactive 
substance 
dependence; 
other 
dementia; 
brain 
trauma, 
other 
neurologic 
disease 
42 IV infusion 
of Cere 
10mL, 30mL 
or 60 mL 
five times a 
week for 4 
weeks and 
then two 
times a week 
for 8 weeks 
Panisset2 
(2002) 
Double 
blind 
RCT 
195 60+ diagnosis of 
AD, mini 
mental state 
exam(MMSE) 
from 10-26, 
Mod. 
Ischemia 
scale <5, 
caregiver 
regularly 
present, 
CT/MRI 
within 12 
months 
Pt with any 
psychiatric 
disorder, or 
psychoactive 
substance 
dependence; 
other 
dementia; 
brain 
trauma, 
other 
significant 
ilness 
16 IV infusion 
of Cere 30 
mL five 
times a week 
for 4 weeks 
Ruether3 
(2001) 
Double 
blind 
RCT 
149 50-85 diagnosis of 
AD, mini 
mental state 
exam(MMSE)  
from 14-24, 
Mod. 
Ischemia 
scale <5, 
CT/MRI 
within 12 
months 
Pt with any 
psychiatric 
disorder, or 
psychoactive 
substance 
dependence; 
other 
dementia; 
brain trauma 
8 IV infusion 
of Cere 30 
mL five 
times a week 
for 4 weeks, 
2 months 
therapy free, 
and repeat 
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OUTCOMES MEASURED 
  Three randomized controlled studies measured improvement in cognitive and global 
impairment in patients with AD using a combination of either ADAS-cog(clinician rated test 
measuring cognitive function), CIBIC+(clinician based interview of patient to assess global 
change), or CGI(clinician assessment of mental deterioration). ADAS-cog evaluations cover 
orientation, memory, language, and understanding.  CIBIC+ and CGI evaluations examine 
activities of daily living and behavior. All outcomes measured were patient oriented outcomes 
(POEMs) and evaluations were conduction at baseline and throughout the studies. The clinician 
evaluated patients through a direct patient interview, and patient caregiver input was used with 
CIBIC+. Evaluations with the tests mentioned were made under double-blind conditions.  
RESULTS 
 The study conducted by Alvarez et al was a 24 week, double blind, randomized 
controlled study between Cerebrolysin and a visually matched placebo. In total 65 individuals 
were randomized and treated with 30 mL Cerebrolysin and 58 with placebo.  The Cere group 
was infused with 30mL Cerebrolysin 5 days a week for 4 weeks, and then 2 days a week for 8 
weeks.1 The placebo group regimen was the same. Post-treatment phase included observing for 
continued effects from previous treatment. Cognitive effects were based on ADAS-cog scores, 
measure of cognition through clinician based interview and performance testing that covers 
memory, orientation language, and comprehension on 70 point scale.  Cerebrolysin had no 
statistically significant effects on cognition with 36.9% of Cerebrolysin patients showing 
improvement and 24.1% of placebo patients improving (p=.069) as displayed by Table 2. At the 
study endpoint overall the patients in Cerebrolysin group performed better in cognitive testing 
than baseline, while patients on placebo had deteriorated by about 2 points in ADAS-cog 
Champion, Cerebrolysin and Alzheimer’s, 8 
 
evaluations. Global functioning outcomes in this study were measured through an evaluation 
with CIBIC+, which correlates behavior and activities of daily living. 60% of the patients treated 
with 30 mL Cerebrolysin experienced an improvement in global functioning while only 20.7% of 
placebo patients improved (Table 3). The most common adverse effects recorded throughout the 
study were UTI and depression. 50.7% of subjects in the Cerebrolysin treatment group 
experienced atleast one AE, while 60% of placebo subjects recorded one AE(Table 3). 2 subjects 
in the Cerebrolysin group experienced serious AEs. Only one of the serious AEs proved a causal 
relationship in which the patient developed bacteremia from IV administration.  
Table 2: Increase in cognitive functioning in patients treated with 30 mL Cere compared to 
placebo 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed 
to treat (NNT) 
24.1% 36.9% .5% 12.8% 8 
 
Table 3: Increase in global function in patients treated with 30mL Cere compared to placebo 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed 
to treat (NNT) 
20.7% 60% 1.89% 39.3% 3 
 
Table 4: Total adverse events recorded during Alverez et al study 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative risk 
inrease (RRI) 
Absolute risk 
increase (ARI) 
Numbers needed 
to harm (NNH) 
60%  50.7%  -.016%  -9.3% -10 
 
 Ruether et al. conducted a 28 week, double blind, randomized controlled study between 
Cerebrolysin and a visually matched placebo.  In total 76 individuals were randomized and 
treated with 30 mL Cerebrolysin and 70 with placebo. The groups were infused with 30mL 
Cerebrolysin 5 days a week for 4 weeks, a 2 month treatment free interval, and repeated the same 
regimen.3 The placebo group matched this regimen using normal saline. After the treatment 
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phase patients were followed for continued effects. The mean difference in CGI, on an 8 point 
scale, between Cerebrolysin and placebo was .42 in favor of Cere.3 Patients with CGI score less 
than 5 were considered to have a positive global response to therapy. At the end of the study 
45.9% of Cere treated patients showed a positive global response compared to 28.6% in the 
placebo group.3 The cognitive domain, measured using ADAS-cog, proved significant effects by 
Cerebrolysin. At the end of the active treatment phase a significant treatment effect was shown 
with 43.7% of Cere patients compared to 15.7% of placebo patients showing improvement.3 At 
28 weeks placebo pts scores had deteriorated by a mean of 1.6 points in the ADAS-cog, and 
patients on Cere maintained baseline, p=.016. Correlation between global and cognitive 
improvements were seen in 57.4% Cere treated patients and 27.5% of placebo patients with a  p 
of .006  and 95% CI of -.12/-072(table 5). Incidence of adverse effects was similar in both 
groups with 43.4% in Cere group and 38.0% in placebo group have atleast one AE(Table 6). The 
most common adverse effects were vertigo, headache, increased sweating, and nausea.3 Cere 
caused no significant changes in vital signs and no deaths in this study.3 The absolute risk 
increase was 5% with most adverse events being mild(38.2%) and similar severe AEs rates in 
both groups; 1.2% less severe AEs in favor of Cerebrolysin.3 
 Table 5: Correlated increase in global functioning and cognitive ability with treatment of 
Cere compared to placebo 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed 
to treat (NNT) 
27.5% 57.4% 1.09% 29.9% 4 
 
 Table 6: Total adverse events recorded during the study 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Numbers needed 
to harm (NNH) 
38% 43.4% .014% 5.4% 19 
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Panisset et al conducted a 24 week, double blind, randomized controlled study between 
Cerebrolysin and a visually matched placebo.2 In total 95 patients were randomized and treated 
with Cerebrolysin, and 94 patients treated with placebo.2 The groups were infused with either 
30mL Cerebrolysin or placebo on 5 days a week for 4 weeks. Following the active treatment 
phase the patients were observed to determine long term efficacy. The scope of global 
functioning was measured using CIBIC+, a clinician based interview assessing cognitive state, 
behavior, and activities of daily living on a scale of 0(marked improvement)-7(marked 
deterioration). Mean change in CIBIC+ at the end of active treatment 3.82 ± .09 for placebo and 
3.88 ± .07 for Cerebrolysin.2 At Week 12, two months following end of treatment, patients 
whom received Cerebrolysin had a mean difference of -.21 points on CIBIC+ in favor of 
Cere(95% CI=-.5-.08, p=.033) .2 Week 12 revealed global improvement in 76% of treated 
patients compared to 57% in patients on placebo, as shown in table 7. At the end of the study the 
mean change in CIBIC+ was 4.46 ± .12 for placebo and 4.42 ± .12 for Cerebrolysin, which are  
not statistically significant effects at 6 months.2 By the end of the study the mean difference in 
CIBIC+ was .4 between the groups.2 The cognitive effects of Cerebrolysin were measured using 
evaluation with ADAS-cog. Cognitive effects were minimal and insignificant at all points in the 
study. The ADAS-cog mean score at week 12, 2 months after active treatment, was -.88 ± .61 for 
placebo and .04 ± .64 for Cere, p value = .284.2 At the end of treatment ADAS-cog mean 
difference was 1.81 points.2 The incidence of atleast one adverse event was 64% in Cerebrolysin 
patients and 73% in placebo patients.2  No change in vital signs were observed with the use of 
Cere and 1 death occurred ten weeks after last infusion due to pneumonia.2 The most common 
AEs in patients on Cere were headache(13%) and dizziness(8%), and placebo had similar rates at 
11% and 12% respectively.2 
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 Table 7: Increase in global functioning in patients treated with 30 mL Cere compared to 
placebo 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed 
to treat (NNT) 
57% 76% 0.33% 19% 5 
 
Table 8: Total adverse events recorded during the study 
Control event 
rate (CER) 
Experimental 
event rate (EER) 
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Numbers needed 
to treat (NNH) 
73% 64% -.12% -9% -11 
 
DISCUSSION  
 The studies covered in this review covered Cerebrolysin as a possible treatment to stop 
and potentially reverse the pathologic process of AD. All studies performed and evaluated in this 
review were controlled, double blind research over a significant period of time with reputable 
evaluation measures.  
The studies were limited by the insufficient evidence suggesting appropriate Cerebrolysin 
treatment frequency and schedule. Patients between each of the three studies were subject to 
different treatment schedules. Ruether et al treated patients for 8 weeks, Alvarez et al. for 12 
weeks, and Panisseta et al for 4 weeks. None of the studies administered Cerebrolysin at the 
same frequency throughout their respective study. Alvarez, Ruether, and Panisset et al. studied 
populations of 123, 146, and 183 respectively. Each sample size was significantly large, diverse, 
and studied over 6-7 month intervals.  
 Cerebrolysin is a peptide preparation with neurotrophic activity. It mimics the effects of 
endogenous neurotrophic factors. Neurotrophic factors regulated nervous tissue functions in a 
healthy environment. Natural NTFs cannot cross BBB due to complex three-dimensional 
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complexion, but the active ingredient in Cerebrolysin, neuropeptides, can. Cerebrolysin induces 
neuronal sprouting, neurogenesis, and neuroplasticity. The concern with this medication is that it 
is extracted from pig brain and all of its components are not completely understood. It is not 
currently FDA approved for the use of Alzheimer’s disease in the US although it is used in other 
numerous other countries. The availability of Cerebrolysin is a concern if it progresses to 
become a widely used commercial product because it is not a synthetic product. The 
administration of Cerebrolysin is via IV infusion, which is another concern towards its 
accessibility, long term use, and insurance coverage.  
CONCLUSIONS 
 The evidence for Cerebrolysin as an effective treatment for AD is inconclusive. The 
efficacy of Cerebrolysin was contradictory in the three studies analyzed in this review. The 
effects on ADLs and behavior, measured by CIBIC+ and CGI, were significant in studies 
performed by Ruether et al. and Panisset et al. The study performed by Alvarez et al. found 
borderline but insignificant effects on ADLs and behavior with a p-value of .069 and wide 95% 
CI.1 Evidence for improvement in cognitive function with use of Cerebrolysin in AD is also 
contradictory. Studies by Alvarez et al. and Panisset et al. found insignificant effects on 
cognitive functioning, measured by ADAS-cog, but Ruether et al. found significant improvement 
in cognitive functioning. Further studies are encouraged to clarify the efficacy of Cerebrolysin in 
AD.  
 The treatment regimen for all three studies was significantly different and offers an area 
to focus improvement. The Ruether et al. study is the only study that found global and cognitive 
improvements and incorporated a regimen of 5 days a week for 4 weeks, a 2 month treatment 
free interval, and then another 5 weeks of treatment.3 Using a treatment plan that has proven to 
be effective may solidify the effects of Cerebrolysin on AD patients. There have been several 
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other studies performed, with the most recent in 2012. In the design of future studies the all 
screening parameters used in these studies would be efficient in selecting an unbiased patient 
population, using the treatment regimen stated above, and exploring the influences of increased 
frequency of Cerebrolysin administration.  
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